NDA 022454 · Ge Hlthcare INC
Datscan
Ioflupane I-123 · Intravenous · Radioactive Diagnostic Agent
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Apr 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Jan 14, 2011
Approved uses
2
Original approval plus efficacy supplements
Registered trials
17
5 Phase 3, 0 recruiting
FAERS reports
541
90 serious, 7 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 24, 2026.
DATSCAN is indicated as an adjunct to other diagnostic evaluations for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging in adult patients with: suspected Parkinsonian syndromes (PS) or suspected dementia with Lewy bodies (DLB). DATSCAN is a radioactive diagnostic agent indicated as an adjunct to other diagnostic evaluations for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging in adult patients with: suspected Parkinsonian syndromes (PS) or suspected dementia with Lewy bodies (DLB). ( 1 )
Mechanism: The active drug substance in DATSCAN is N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-[ 123 I]iodophenyl)nortropane or ioflupane I 123. In vitro , ioflupane binds reversibly to the human dopamine transporter (DaT) (Ki = 0.62 nM; IC 50 = 0.71 nM). Autoradiography of post-mortem human brain slices exposed to radiolabeled ioflupane shows concentration of the radiolabel in striatum (caudate nucleus and putamen). The specificity of the binding of ioflupane I 125 to dopamine transporter was demonstrated by competition studies with the DaT inhibitor GBR 12909 (a dopamine reuptake inhibitor), the serotonin...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 1, 2022 Supplement 10 · Efficacy LetterLabel
- Jan 14, 2011 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelSummary ReviewReview
1 products under this application
- DATSCAN · IOFLUPANE I-123 5mCi/2.5ML (2mCi/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Ioflupane I-123" as an intervention, any sponsor and status, largest first.
Ken Marek, MDAcademic, hospital or other
NCT01141023 · 952 participants · Start Jun 2010 · Primary completion Jun 30, 2020
Drug: DaTscan · For: Parkinson Disease
Sites: Birmingham, Alabama; Sun City, Arizona; La Jolla, California · 34 sites in all
- DaTSCAN Imaging in Aging and Neurodegenerative DiseaseEnrolling by invitation
Mayo ClinicAcademic, hospital or other
NCT01453127 · 500 participants (planned) · Start Oct 2011 · Primary completion Dec 2026
Drug: I-123 Ioflupane solution injection prior to SPECT scan (DaTscan) · For: Dementia; Parkinsonism; Mild Cognitive Impairment and 1 more
Sites: Rochester, Minnesota
- Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body DementiaPivotal-lookingCompleted
GE HealthcareIndustry
NCT00209456 · 326 participants · Start Nov 2003
Drug: DatSCAN · For: Lewy Body Dementia; Non-DLB Dementia; Alzheimer's and 1 more
Sites: Ismaning, Germany
- A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese PatientsPivotal-lookingCompleted
GE HealthcareIndustry
NCT04193527 · 172 participants · Start Jun 28, 2020 · Primary completion Dec 20, 2021
Drug: DaTSCAN™ Ioflupane (123I) Injection · For: Parkinsonian Syndrome; Parkinson Disease(PD); Multiple System Atrophy (MSA) and 2 more
Sites: Beijing, China; Guangdong, China; Nanjing, China · 10 sites in all
- [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential TremorPivotal-lookingCompleted
GE HealthcareIndustry
NCT04265209 · 152 participants · Start Dec 1, 2021 · Primary completion Aug 2, 2024
Drug: SPECT; PET · For: Parkinson Disease; Essential Tremor
Sites: Bobigny, France; Bordeaux, France; Clermont-Ferrand, France · 16 sites in all
Weill Medical College of Cornell UniversityAcademic, hospital or other
NCT03675282 · 82 participants · Start Aug 14, 2018 · Primary completion Apr 23, 2024
Drug: (11C)PE2I; Ioflupane · For: Parkinson Disease; REM Sleep Behavior Disorder; Healthy
Sites: New York, New York
Nantes University HospitalAcademic, hospital or other
NCT03230526 · 31 participants · Start Apr 16, 2018 · Primary completion May 6, 2024
Drug: [18F]DPA-714 PET scan · For: Parkinson Disease
Sites: Nantes, France; Rennes, France; Tours, France · 4 sites in all
Institute for Neurodegenerative DisordersAcademic, hospital or other
NCT00129181 · 30 participants · Start Jan 2005 · Primary completion Dec 2006
Drug: cabergoline; carbidopa/levodopa · For: Parkinson Disease; Parkinsonian Syndrome
Sites: Innsbruck, Austria; Vienna, Austria; Leipzig, Germany · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- no adverse event263
- radioisotope scan abnormal148
- drug ineffective128
- injection site pain59
- drug interaction49
- parkinsonism26
- burning sensation24
- false positive radioisotope investigation result16
- dopamine transporter scintigraphy abnormal12
- nausea12
- product quality issue11
- headache10
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 7 |
| 2015 | 16 |
| 2016 | 27 |
| 2017 | 74 |
| 2018 | 63 |
| 2019 | 55 |
| 2020 | 44 |
| 2021 | 37 |
| 2022 | 32 |
| 2023 | 37 |
| 2024 | 72 |
| 2025 | 50 |
| 2026 | 25 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- I123-FP-CIT (DaTSCAN) SPECT beyond the Most Common Causes of Parkinsonism: A Systematic Review.
Quintas S, Sanles-Falagan R, Berbís MÁ · Mov Disord Clin Pract 2024 · Systematic Review
- N-Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson's Disease.
Monti DA, Zabrecky G, Kremens D, et al. · Clin Pharmacol Ther 2019 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies.
Prins ND, de Haan W, Gardner A, et al. · J Prev Alzheimers Dis 2024 · Clinical Trial, Phase II, Randomized Controlled Trial
- Diagnostic accuracy of ¹²³I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-analysis of published studies.
Papathanasiou ND, Boutsiadis A, Dickson J, et al. · Parkinsonism Relat Disord 2012 · Meta-Analysis, Review
- [Effectiveness of 123I-ioflupane (DaTSCAN) in the diagnosis of Parkinsonian syndromes. A systematic review].
Puñal Riobóo J, Varela Lema L, Serena Puig A, et al. · Rev Esp Med Nucl 2007 · Systematic Review
- [¹²³I]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson's disease and vascular or drug-induced parkinsonisms: a meta-analysis.
Brigo F, Matinella A, Erro R, et al. · Eur J Neurol 2014 · Meta-Analysis
Sponsor: Ge Hlthcare INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.